Undated
Dave Ricks says tirzepatide is a dual-acting drug that uses two gut hormones, GLP-1 and GIP.
“Tirzepatide is a dual acting. So it uses two hormones.”
Topic
7 facts from 3 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
Undated
Dave Ricks says tirzepatide is a dual-acting drug that uses two gut hormones, GLP-1 and GIP.
“Tirzepatide is a dual acting. So it uses two hormones.”
Undated
Dave Ricks says tirzepatide reduces body weight by about 20 percent on average.
“And so it's really helping reduce weight on average 20 % of body weight.”
Undated
Dave Ricks says a Lilly study showed tirzepatide reduced new diabetes diagnoses by 94 percent.
“now we're demonstrating it also affects the downstream diseases, like we just showed, it reduced new diabetes diagnosis by 94%.”
Undated
Dave Ricks says Eli Lilly has now caught up with supply of its obesity drug, but only just.
“we have a situation where we're now caught up with supply, but just”
Undated
Tirzepatide, Lilly's third-generation drug in this class, acts on two gut hormones, GLP-1 and GIP.
“So it's GLP plus GIP, two different gut hormones.”
Undated
According to David Ricks, weight loss was a design goal for tirzepatide but not for Lilly's earlier GLP-1 drugs such as exenatide and dulaglutide.
“It was a design goal for Trisepetide, which is these two actions for weight loss.”
Undated
Tirzepatide's extended C-terminal tail is not found in natural human GLP-1 and is taken from exenatide.
“its extended C-terminus is not found on natural human GLP-1. And you want to guess why? I'll give you three seconds. One, two, three. Well, it's actually taken directly from exenatide.”
Episodes